Cap analog
A collection page of Yeasen - Leading Innovation in Molecular Enzymes and Reagents
About
The development history of the mRNA cap stems from in-depth research into gene expression in eukaryotes. The mRNA cap is a modification at the 5' end of mRNA molecules, playing a crucial role in translation, stability, and immune response. In the early 1970s, scientists first discovered the capping structure at the 5' end of eukaryotic mRNA. This cap consists of a 7-methylguanosine (m7G) linked to the mRNA via a 5'-5' triphosphate bond. Scientists later discovered that the mRNA cap not only includes the basic m7G structure but can also have methylations on nearby nucleotide residues, forming more complex Cap 1 and Cap 2 structures. These modifications increased mRNA stability and reduced immune system recognition of exogenous mRNA. Cap 1 and Cap 2 are widely used in the synthesis of mRNA for vaccines and gene therapies. Learn More
Sign in to see the ads landing on this page and its link graph.
Sign in to see all findings